{"id":"testim","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.2 )] . Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.1 )]. Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Application site reaction","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased hematocrit","drugRate":"2.8%","severity":"common","organSystem":""},{"effect":"Increased hemoglobin","drugRate":"2.3%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"2.7%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Depression with suicidal ideation","drugRate":"","severity":"serious"},{"effect":"Mood swings","drugRate":"","severity":"serious"},{"effect":"Urinary tract infection","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Testosterone gel","testosteron","Testim® is the brand name for testosterone gel."],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Testim","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:29:34.157409+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:29:46.767192+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:29:39.572945+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Testim","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:29:39.906488+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:29:40.964863+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL386630/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:29:40.623638+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"9f2aae1f-898d-4955-be31-678e0cf85395","title":"TESTIM (TESTOSTERONE) GEL [ENDO USA, INC.]"},"aiSummary":"Testim, marketed by Endo Pharmaceuticals, is a testosterone replacement therapy with a key composition patent expiring in 2028. The drug's market position is bolstered by its established presence and ongoing revenue generation. However, the primary risk lies in the potential increase in competition following the patent expiry in 2028.","ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T00:11:51.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:29:46.767258+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07481942","phase":"","title":"Body Composition Assessment in Transgender Population.","status":"COMPLETED","sponsor":"Celia Bañuls","startDate":"2017-01-01","conditions":"Transgender","enrollment":70},{"nctId":"NCT04675788","phase":"PHASE4","title":"Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening","status":"COMPLETED","sponsor":"Indiana University","startDate":"2021-09-02","conditions":"Long QT Syndrome, Abnormalities, Drug-Induced","enrollment":73},{"nctId":"NCT04798469","phase":"PHASE2","title":"Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-01-10","conditions":"Opioid Use, Pain, Hypogonadism, Male","enrollment":150},{"nctId":"NCT07476001","phase":"PHASE2","title":"Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":12},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT05964920","phase":"PHASE2, PHASE3","title":"Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone?","status":"COMPLETED","sponsor":"Norwegian School of Sport Sciences","startDate":"2024-09-01","conditions":"Healthy Aging, Age-Related Sarcopenia, Testosterone Deficiency","enrollment":45},{"nctId":"NCT07278362","phase":"PHASE4","title":"Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05-31","conditions":"Prostate Cancer, Hypogonadism, Male","enrollment":35},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":14},{"nctId":"NCT06689085","phase":"PHASE3","title":"52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism","status":"RECRUITING","sponsor":"Halozyme Therapeutics","startDate":"2025-03-07","conditions":"Hypogonadism, Male","enrollment":100},{"nctId":"NCT07143279","phase":"EARLY_PHASE1","title":"Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-02-11","conditions":"Hypotestosteronism, Palliative Care","enrollment":20},{"nctId":"NCT04558866","phase":"PHASE2","title":"Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2021-06-09","conditions":"Prostate Cancer","enrollment":51},{"nctId":"NCT04731376","phase":"PHASE1","title":"Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-01-25","conditions":"Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder","enrollment":56},{"nctId":"NCT06733350","phase":"PHASE4","title":"Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance","status":"SUSPENDED","sponsor":"Roswell Park Cancer Institute","startDate":"2025-01-15","conditions":"Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8","enrollment":600},{"nctId":"NCT07092527","phase":"PHASE4","title":"Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-12-05","conditions":"Transgenderism, Reproductive Issues","enrollment":80},{"nctId":"NCT06039371","phase":"PHASE2","title":"Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-05-21","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":69},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07328542","phase":"PHASE4","title":"Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men","status":"NOT_YET_RECRUITING","sponsor":"Azurity Pharmaceuticals","startDate":"2026-02","conditions":"Hypogonadism, Male","enrollment":144},{"nctId":"NCT06130449","phase":"EARLY_PHASE1","title":"Testosterone and Neural Function","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-04-01","conditions":"Spinal Cord Injury","enrollment":15},{"nctId":"NCT06084338","phase":"PHASE2","title":"Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-12-14","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT04895306","phase":"PHASE2","title":"Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-15","conditions":"Pain, Opioid Use, Androgen Deficiency","enrollment":40},{"nctId":"NCT03887936","phase":"PHASE4","title":"Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2019-10-01","conditions":"Type 2 Diabetes Mellitus, Hypogonadism","enrollment":92},{"nctId":"NCT05914324","phase":"NA","title":"Outpatient Pediatric Pulse Oximeters in Africa","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-11-04","conditions":"Child, Infant, Respiratory Tract Infections","enrollment":1200},{"nctId":"NCT06594926","phase":"PHASE2","title":"Working Out M0 Bipolar Androgen Therapy","status":"RECRUITING","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2024-08-14","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT04807894","phase":"PHASE4","title":"Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2020-11-01","conditions":"Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder","enrollment":100},{"nctId":"NCT06100705","phase":"PHASE2","title":"Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-12-20","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":26},{"nctId":"NCT03516812","phase":"PHASE2","title":"Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2018-08-29","conditions":"Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":36},{"nctId":"NCT06291675","phase":"","title":"Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2023-03-03","conditions":"Gender Dysphoria, Hormone Therapy Induced Morphologic Change","enrollment":50},{"nctId":"NCT07187947","phase":"","title":"Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-07-18","conditions":"Gender Incongruence, Cardiovascular (CV) Risk, Cardiovascular Disease Risk Factor","enrollment":500},{"nctId":"NCT03716739","phase":"PHASE2","title":"Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-03-19","conditions":"Prostate Cancer","enrollment":136},{"nctId":"NCT05081193","phase":"PHASE2","title":"Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-03-07","conditions":"Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":15},{"nctId":"NCT03576001","phase":"PHASE2","title":"Multimodality Intervention for Function and Metabolism in SCI","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-08-23","conditions":"Spinal Cord Injuries","enrollment":84},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT02256865","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2014-10","conditions":"Insulin Resistance","enrollment":40},{"nctId":"NCT06385509","phase":"PHASE4","title":"A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2024-05-10","conditions":"Hypogonadism","enrollment":110},{"nctId":"NCT04601233","phase":"PHASE4","title":"Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Tulane University","startDate":"2026-06","conditions":"Multiple Sclerosis, Erectile Dysfunction, Testosterone Deficiency","enrollment":20},{"nctId":"NCT06455969","phase":"PHASE4","title":"Adaptions and Resiliency to Multi-Stressor OpeRations","status":"RECRUITING","sponsor":"Bradley Nindl","startDate":"2024-07-15","conditions":"Musculoskeletal Injury, Hypogonadism","enrollment":120},{"nctId":"NCT06247267","phase":"","title":"The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2021-03-09","conditions":"Hypogonadism, Gender Identity Dysphoria","enrollment":75},{"nctId":"NCT07085715","phase":"","title":"Pan-Viral Screening and Linkage to Care Among GBMSM and Trans Women in Spain","status":"NOT_YET_RECRUITING","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2025-10","conditions":"HIV, Hepatitis B, Hepatitis C","enrollment":500},{"nctId":"NCT06450405","phase":"PHASE4","title":"Androgen Effects on the Reproductive Neuroendocrine Axis","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2025-02-26","conditions":"Transgenderism, Reproductive Issues","enrollment":2},{"nctId":"NCT04363164","phase":"PHASE2","title":"Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-08-19","conditions":"Castration Resistant Metastatic Prostate Cancer","enrollment":150},{"nctId":"NCT03910738","phase":"PHASE2","title":"TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-10-29","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":40},{"nctId":"NCT05381831","phase":"PHASE4","title":"Natesto Spermatogenesis Reboot","status":"COMPLETED","sponsor":"University of Florida","startDate":"2022-06-01","conditions":"Hypogonadism, Male","enrollment":13},{"nctId":"NCT03522064","phase":"PHASE2","title":"Bipolar Androgen Therapy + Carboplatin in mCRPC","status":"RECRUITING","sponsor":"St Vincent's Hospital, Sydney","startDate":"2018-07-30","conditions":"Castration-resistant Prostate Cancer, Homologous Recombination Deficiency","enrollment":30},{"nctId":"NCT06111209","phase":"PHASE2","title":"The Anabolic Effect of Testosterone on Pelvic Floor Muscles","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-02-15","conditions":"Stress Urinary Incontinence, Menopause","enrollment":30},{"nctId":"NCT04460872","phase":"PHASE2","title":"Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury","status":"RECRUITING","sponsor":"North Florida Foundation for Research and Education","startDate":"2021-01-31","conditions":"Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System","enrollment":21},{"nctId":"NCT04833426","phase":"PHASE3","title":"Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy","status":"RECRUITING","sponsor":"Canisius-Wilhelmina Hospital","startDate":"2022-12-12","conditions":"Prostatic Neoplasms, Hypogonadism, Testosterone Deficiency","enrollment":140},{"nctId":"NCT06188767","phase":"NA","title":"Testosterone-induced Muscle Memory and Underlying Mechanisms","status":"RECRUITING","sponsor":"Morten Hostrup, PhD","startDate":"2025-04-01","conditions":"Skeletal Muscle Physiology","enrollment":30},{"nctId":"NCT05249634","phase":"PHASE2","title":"Testosterone Treatment in Men with Chronic Kidney Disease","status":"RECRUITING","sponsor":"St. Louis University","startDate":"2022-03-15","conditions":"Hypogonadism, Male, Kidney Disease, Chronic","enrollment":20},{"nctId":"NCT05487794","phase":"NA","title":"Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2022-09-01","conditions":"Testosterone, Transsexualism, Hematologic Diseases","enrollment":46},{"nctId":"NCT05435222","phase":"NA","title":"Evaluation of a Male-specific Psychotherapeutic Program for Major Depressive Disorders","status":"RECRUITING","sponsor":"Andreas Walther","startDate":"2023-03-15","conditions":"Major Depressive Disorder","enrollment":244},{"nctId":"NCT04456296","phase":"PHASE4","title":"A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2020-06-30","conditions":"Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism","enrollment":673},{"nctId":"NCT06351501","phase":"PHASE3","title":"Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-25","conditions":"Gender Dysphoria","enrollment":60},{"nctId":"NCT04049331","phase":"PHASE2","title":"Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone","status":"RECRUITING","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2021-03-22","conditions":"Hypogonadism, Male, Fatigue Syndrome, Chronic","enrollment":240},{"nctId":"NCT03721497","phase":"PHASE4","title":"Testosterone in Bariatric Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Esbjerg Hospital - University Hospital of Southern Denmark","startDate":"2020-12-17","conditions":"Bariatric Surgery Candidate, Male Hypogonadism, Muscle Loss","enrollment":64},{"nctId":"NCT02432261","phase":"PHASE1","title":"Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men","status":"COMPLETED","sponsor":"Kimberly Myer","startDate":"2015-04","conditions":"Healthy","enrollment":44},{"nctId":"NCT04321551","phase":"PHASE4","title":"Hormone Secretion in Transgender Males","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2023-07-01","conditions":"Transgender, Healthy","enrollment":""},{"nctId":"NCT06462482","phase":"PHASE4","title":"Peri-Operative Testosterone Administration in Primary Hip Arthroscopy","status":"NOT_YET_RECRUITING","sponsor":"American Hip Institute","startDate":"2025-01","conditions":"Femoro Acetabular Impingement","enrollment":60},{"nctId":"NCT06608914","phase":"PHASE4","title":"Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"American Hip Institute","startDate":"2025-01","conditions":"Osteoarthritis, Hip","enrollment":60},{"nctId":"NCT06592144","phase":"PHASE4","title":"TESTO-TRIAL: Use of Testosterone in Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Leticia Maria Defendi Barboza Marson","startDate":"2024-09-09","conditions":"Weaning Failure, Muscle Weakness, Mechanical Ventilation Complication","enrollment":94},{"nctId":"NCT02990533","phase":"PHASE1","title":"Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2016-09","conditions":"Aging","enrollment":80},{"nctId":"NCT05103228","phase":"NA","title":"Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders","status":"COMPLETED","sponsor":"Peter Kovacs MD","startDate":"2021-12-02","conditions":"Infertility, Ovarian Dysfunction","enrollment":190},{"nctId":"NCT02514629","phase":"PHASE3","title":"Testosterone, Metformin, or Both, for Hypogonadism in Obese Males","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2013-07-04","conditions":"Hypogonadism, Obesity","enrollment":107},{"nctId":"NCT06393634","phase":"EARLY_PHASE1","title":"Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration","status":"COMPLETED","sponsor":"Sports Medicine Research and Testing Laboratory","startDate":"2024-11-27","conditions":"Healthy","enrollment":14},{"nctId":"NCT04593680","phase":"NA","title":"Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2022-01-24","conditions":"Drug Interaction","enrollment":20},{"nctId":"NCT02733133","phase":"PHASE2","title":"Product Transference Study of Testagen™ TDS®-Testosterone","status":"UNKNOWN","sponsor":"Transdermal Delivery Solutions Corp","startDate":"2016-11","conditions":"Hypogonadotropism","enrollment":96},{"nctId":"NCT06082817","phase":"PHASE2","title":"An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD","status":"NOT_YET_RECRUITING","sponsor":"San Diego Sexual Medicine","startDate":"2025-01-01","conditions":"Hypoactive Sexual Desire Disorder","enrollment":30},{"nctId":"NCT05318755","phase":"","title":"China Gender-affirming Hormone Therapy Study","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2022-04-16","conditions":"Transgender, Gender Incongruence","enrollment":240},{"nctId":"NCT04558567","phase":"PHASE4","title":"Vogelxo(R) ABPM Study in Hypogandal Men","status":"COMPLETED","sponsor":"Upsher-Smith Laboratories","startDate":"2020-08-28","conditions":"Hypogonadism, Male","enrollment":122},{"nctId":"NCT00080756","phase":"PHASE2","title":"Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2004-03-11","conditions":"brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer","enrollment":11},{"nctId":"NCT00645658","phase":"NA","title":"Testosterone Replacement Therapy in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"Palo Alto Veterans Institute for Research","startDate":"2007-08","conditions":"Kidney Failure, Kidney Diseases","enrollment":17},{"nctId":"NCT05156606","phase":"NA","title":"Testosterone & Tamoxifen Trial","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2022-11-10","conditions":"Male Breast Cancer","enrollment":5},{"nctId":"NCT03339635","phase":"PHASE2","title":"Short-term Testosterone Replacement in Testicular Cancer Survivors","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2018-12-21","conditions":"Testicular Cancer","enrollment":32},{"nctId":"NCT04685993","phase":"PHASE2","title":"A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2020-11-11","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":25},{"nctId":"NCT06489457","phase":"PHASE3","title":"The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2020-09-20","conditions":"Type 2 Diabetes Mellitus, Obesity, Functional Hypogonadism","enrollment":25},{"nctId":"NCT04467697","phase":"PHASE3","title":"Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men","status":"COMPLETED","sponsor":"Marius Pharmaceuticals","startDate":"2018-09-18","conditions":"Hypogonadism, Male","enrollment":155},{"nctId":"NCT02418572","phase":"PHASE3","title":"Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial","status":"TERMINATED","sponsor":"Fundacion Dexeus","startDate":"2015-04","conditions":"Infertility, Poor Ovarian Response","enrollment":290},{"nctId":"NCT04717362","phase":"EARLY_PHASE1","title":"The Effects of Natesto For Treatment Of Hypogonadism","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2024-03-01","conditions":"Hypogonadism, Male, Infertility, Male, Testosterone Deficiency","enrollment":""},{"nctId":"NCT06312761","phase":"PHASE1, PHASE2","title":"Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2024-06-01","conditions":"Hypogonadism, Male","enrollment":10},{"nctId":"NCT03851627","phase":"PHASE4","title":"Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism","status":"RECRUITING","sponsor":"Alexandra Kautzky-Willer","startDate":"2022-01-25","conditions":"Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus","enrollment":32},{"nctId":"NCT03518034","phase":"PHASE4","title":"A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-05-03","conditions":"Hypogonadism, Cardiovascular Diseases","enrollment":5246},{"nctId":"NCT05541172","phase":"","title":"Testosterone Undecanoate Replacement Therapy in Boys With Pubertal Delay or Confirmed Hypogonadism","status":"UNKNOWN","sponsor":"Hospital de Niños R. Gutierrez de Buenos Aires","startDate":"2022-03-01","conditions":"Delayed Puberty, Male Hypogonadism","enrollment":27},{"nctId":"NCT03554317","phase":"PHASE2","title":"COMbination of Bipolar Androgen Therapy and Nivolumab","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-05","conditions":"Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer","enrollment":45},{"nctId":"NCT02995330","phase":"PHASE1","title":"Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-09","conditions":"Prostate Cancer","enrollment":3},{"nctId":"NCT00467987","phase":"NA","title":"Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism","status":"TERMINATED","sponsor":"University at Buffalo","startDate":"2007-06-01","conditions":"Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism","enrollment":47},{"nctId":"NCT04327934","phase":"EARLY_PHASE1","title":"Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-12-01","conditions":"Polycystic Ovary Syndrome, Hypertension","enrollment":28},{"nctId":"NCT04551144","phase":"","title":"Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors","status":"TERMINATED","sponsor":"St. Louis University","startDate":"2020-10-06","conditions":"Gender Incongruence, Transgenderism","enrollment":4},{"nctId":"NCT04134091","phase":"PHASE2","title":"The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2019-08-27","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":56},{"nctId":"NCT04983940","phase":"PHASE4","title":"Patient Satisfaction After Switching to Oral Testosterone Undecanoate","status":"COMPLETED","sponsor":"University of Miami","startDate":"2021-06-18","conditions":"Testosterone Deficiency","enrollment":41},{"nctId":"NCT04439799","phase":"PHASE4","title":"A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-08-07","conditions":"Hypogonadism, Male","enrollment":81},{"nctId":"NCT01187485","phase":"PHASE1","title":"A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-06","conditions":"Prostate Cancer","enrollment":15},{"nctId":"NCT00587431","phase":"PHASE2","title":"Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-07","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT03345797","phase":"PHASE1","title":"Evaluation of Testosterone Nasal Gel in Hypogonadal Boys","status":"TERMINATED","sponsor":"Acerus Biopharma Inc.","startDate":"2018-03-01","conditions":"Hypogonadism","enrollment":8},{"nctId":"NCT01460654","phase":"PHASE2","title":"Testosterone and Alendronate in Hypogonadal Men","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2011-10","conditions":"Hypogonadism, Osteopenia, Osteoporosis","enrollment":44},{"nctId":"NCT05825092","phase":"PHASE2","title":"Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2023-07-21","conditions":"Critical Illness","enrollment":600},{"nctId":"NCT02248701","phase":"PHASE2","title":"Testosterone Plus Finasteride Treatment After Spinal Cord Injury","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2017-04-27","conditions":"Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System","enrollment":33},{"nctId":"NCT04523480","phase":"PHASE3","title":"Testopel ® vs. Generic Testosterone Pellets.","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-03-12","conditions":"Hypogonadism","enrollment":75},{"nctId":"NCT03198728","phase":"PHASE3","title":"Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men","status":"COMPLETED","sponsor":"Marius Pharmaceuticals","startDate":"2017-07-05","conditions":"Hypogonadism, Male","enrollment":314},{"nctId":"NCT03123913","phase":"PHASE1","title":"Study of Testosterone and rHGH in FSHD","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2017-12-18","conditions":"Facioscapulohumeral Muscular Dystrophy","enrollment":20},{"nctId":"NCT03678233","phase":"PHASE2","title":"Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-27","conditions":"Hypermetabolism in ICU, Loss of Muscle Mass, Functional Disability After ICU","enrollment":30},{"nctId":"NCT05649605","phase":"NA","title":"Early Mental Response - The EMRE Study","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-03-07","conditions":"Gender Dysphoria, Gender Identity, Gender Issues","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL386630"},"formularyStatus":[],"_approvalHistory":[{"date":"20190530","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20190510","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20021031","type":"ORIG","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20140102","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20210820","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20201130","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20150511","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20140619","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20250711","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20210820","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20090918","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20161025","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20130830","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20201130","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20150409","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20111122","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"},{"date":"20140501","type":"SUPPL","sponsor":"ENDO OPERATIONS","applicationNumber":"NDA021454"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":39,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Testim","genericName":"Testim","companyName":"Endo Pharmaceuticals","companyId":"endo-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:29:46.767258+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}